Effects of bretylium tosylate on voltage-gated potassium channels in human T lymphocytes

Rezso Cáspár, G. Panyi, Dirk L. Ypey, Z. Krasznai, G. Vereb, Carlo Pieri, S. Damjanovich

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Using the patch-clamp technique, we determined that bretylium tosylate, a quaternary ammonium compound possessing immunomodulating activity, decreased the whole-cell K+ current in human T lymphocytes, in a dose-dependent manner, in the 0.05-5 mM extracellular concentration range. Bretylium tosylate prolonged the recovery from inactivation and accelerated the inactivation and deactivation of the K+ current but did not influence the kinetics of activation or the voltage dependence of activation and steady state inactivation of the K+ conductance. The percentage of drug-induced block was independent of membrane potential K+ channel block by bretylium tosylate was partially and slowly removable by washing with drug-free extracellular solution. Bovine serum albumin (10 mg/ml) in the bath lifted the drug-induced block almost instantaneously, although not completely. In control experiments bovine serum albumin increased the inactivation time constant of the K+ channels but left the peak K+ current amplitude unaffected. On the basis of the experimental evidence, a gating-dependent allosteric interaction is suggested for the mechanism of drug action. The effective dose range, time of exposure, and reversibility of bretylium tosylate-induced K+ channel block correlated well with the same parameters of the drug-induced inhibition of T lymphocyte activation. The reported effects of bretylium tosylate on T cell mitogenesis can be regarded partly as a consequence of its blocking effects on voltage-gated K+ channels.

Original languageEnglish
Pages (from-to)762-766
Number of pages5
JournalMolecular Pharmacology
Volume46
Issue number4
Publication statusPublished - Oct 1994

Fingerprint

Bretylium Tosylate
Voltage-Gated Potassium Channels
T-Lymphocytes
Pharmaceutical Preparations
Bovine Serum Albumin
Quaternary Ammonium Compounds
Patch-Clamp Techniques
Lymphocyte Activation
Baths
Membrane Potentials

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of bretylium tosylate on voltage-gated potassium channels in human T lymphocytes. / Cáspár, Rezso; Panyi, G.; Ypey, Dirk L.; Krasznai, Z.; Vereb, G.; Pieri, Carlo; Damjanovich, S.

In: Molecular Pharmacology, Vol. 46, No. 4, 10.1994, p. 762-766.

Research output: Contribution to journalArticle

@article{fcbc455cbab044dd90a4c29b4a0e6d04,
title = "Effects of bretylium tosylate on voltage-gated potassium channels in human T lymphocytes",
abstract = "Using the patch-clamp technique, we determined that bretylium tosylate, a quaternary ammonium compound possessing immunomodulating activity, decreased the whole-cell K+ current in human T lymphocytes, in a dose-dependent manner, in the 0.05-5 mM extracellular concentration range. Bretylium tosylate prolonged the recovery from inactivation and accelerated the inactivation and deactivation of the K+ current but did not influence the kinetics of activation or the voltage dependence of activation and steady state inactivation of the K+ conductance. The percentage of drug-induced block was independent of membrane potential K+ channel block by bretylium tosylate was partially and slowly removable by washing with drug-free extracellular solution. Bovine serum albumin (10 mg/ml) in the bath lifted the drug-induced block almost instantaneously, although not completely. In control experiments bovine serum albumin increased the inactivation time constant of the K+ channels but left the peak K+ current amplitude unaffected. On the basis of the experimental evidence, a gating-dependent allosteric interaction is suggested for the mechanism of drug action. The effective dose range, time of exposure, and reversibility of bretylium tosylate-induced K+ channel block correlated well with the same parameters of the drug-induced inhibition of T lymphocyte activation. The reported effects of bretylium tosylate on T cell mitogenesis can be regarded partly as a consequence of its blocking effects on voltage-gated K+ channels.",
author = "Rezso C{\'a}sp{\'a}r and G. Panyi and Ypey, {Dirk L.} and Z. Krasznai and G. Vereb and Carlo Pieri and S. Damjanovich",
year = "1994",
month = "10",
language = "English",
volume = "46",
pages = "762--766",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

TY - JOUR

T1 - Effects of bretylium tosylate on voltage-gated potassium channels in human T lymphocytes

AU - Cáspár, Rezso

AU - Panyi, G.

AU - Ypey, Dirk L.

AU - Krasznai, Z.

AU - Vereb, G.

AU - Pieri, Carlo

AU - Damjanovich, S.

PY - 1994/10

Y1 - 1994/10

N2 - Using the patch-clamp technique, we determined that bretylium tosylate, a quaternary ammonium compound possessing immunomodulating activity, decreased the whole-cell K+ current in human T lymphocytes, in a dose-dependent manner, in the 0.05-5 mM extracellular concentration range. Bretylium tosylate prolonged the recovery from inactivation and accelerated the inactivation and deactivation of the K+ current but did not influence the kinetics of activation or the voltage dependence of activation and steady state inactivation of the K+ conductance. The percentage of drug-induced block was independent of membrane potential K+ channel block by bretylium tosylate was partially and slowly removable by washing with drug-free extracellular solution. Bovine serum albumin (10 mg/ml) in the bath lifted the drug-induced block almost instantaneously, although not completely. In control experiments bovine serum albumin increased the inactivation time constant of the K+ channels but left the peak K+ current amplitude unaffected. On the basis of the experimental evidence, a gating-dependent allosteric interaction is suggested for the mechanism of drug action. The effective dose range, time of exposure, and reversibility of bretylium tosylate-induced K+ channel block correlated well with the same parameters of the drug-induced inhibition of T lymphocyte activation. The reported effects of bretylium tosylate on T cell mitogenesis can be regarded partly as a consequence of its blocking effects on voltage-gated K+ channels.

AB - Using the patch-clamp technique, we determined that bretylium tosylate, a quaternary ammonium compound possessing immunomodulating activity, decreased the whole-cell K+ current in human T lymphocytes, in a dose-dependent manner, in the 0.05-5 mM extracellular concentration range. Bretylium tosylate prolonged the recovery from inactivation and accelerated the inactivation and deactivation of the K+ current but did not influence the kinetics of activation or the voltage dependence of activation and steady state inactivation of the K+ conductance. The percentage of drug-induced block was independent of membrane potential K+ channel block by bretylium tosylate was partially and slowly removable by washing with drug-free extracellular solution. Bovine serum albumin (10 mg/ml) in the bath lifted the drug-induced block almost instantaneously, although not completely. In control experiments bovine serum albumin increased the inactivation time constant of the K+ channels but left the peak K+ current amplitude unaffected. On the basis of the experimental evidence, a gating-dependent allosteric interaction is suggested for the mechanism of drug action. The effective dose range, time of exposure, and reversibility of bretylium tosylate-induced K+ channel block correlated well with the same parameters of the drug-induced inhibition of T lymphocyte activation. The reported effects of bretylium tosylate on T cell mitogenesis can be regarded partly as a consequence of its blocking effects on voltage-gated K+ channels.

UR - http://www.scopus.com/inward/record.url?scp=0028077755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028077755&partnerID=8YFLogxK

M3 - Article

C2 - 7969057

AN - SCOPUS:0028077755

VL - 46

SP - 762

EP - 766

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 4

ER -